UNION therapeutics A/S announces new paper on clinical potential of the emerging class of PDE4B/D inhibitors published in journal of Dermatology and Therapy
· PDE4-inhibition is a well-established mechanism of action typically used for first line of treatment due to a well-documented safety and tolerability profile · As the understanding of PDE4 inhibition has evolved, PDE4B/D subtype inhibition has demonstrated to be critical in achieving anti-inflammatory effects, and selective PDE4B/D inhibitors may drive higher efficacy than previously approved PDE4 inhibitors · UNION is developing orismilast, a safe oral, PDE4B/D inhibitor with broad anti-inflammatory properties Hellerup, Denmark, November 29, 2023 – UNION therapeutics A/S (